Sally S. Ong, MD, spoke about her study on the impact of individual and neighborhood-level social determinants of health on vision and foveal status at presentation in patients with rhegmatogenous retinal detachments at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.
Yasha Modi, MD, spoke with Modern Retina about the ASRS 2024: The DAVIO phase 2 trial and upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.
Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg
Dr. Khouri discusses the MIGS procedures he performs in his practice and his approach to selecting the most appropriate procedure for each patient.
Dr Khouri presents a case of a glaucoma patient who underwent multiple SLT procedures and would be a good candidate for MIGS.
Dr Khouri discusses selective laser trabeculoplasty (SLT) as a first-line treatment for glaucoma and identifies patients who would be good candidates for this procedure.
Dr Albert S Khouri, MD presents a case of a glaucoma patient and discusses his approach to medical management of glaucoma.
Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.
Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024
Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial
Patrick C. Staropoli, MD, discussed his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa while attending the annual ASRS meeting in Stockholm, Sweden.
Jordana Fein, MD, MS, spoke with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.
Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.
Eleonora Lad, MD, PhD, discusses multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Alan Franklin, MD, PhD, FASRS, a retina specialist in Mobile, Alabama spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage."
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.
Sally S. Ong, MD, spoke with Modern Retina about her research titled, "Individual and neighborhood-level socioeconomic characteristics associated with presenting visual acuity and foveal status in rhegmatogenous retinal detachment" at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
Ashkan Abbey, MD, spoke with Modern Retina about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.
Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, talked about his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa at the annual ASRS meeting in Stockholm, Sweden.
Michael Singer, MD, speaks at the American Society of Retina Specialists meeting
Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions
